Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...

Fears of a slump in its blockbuster weight loss treatment, Wegovy's sales in late September were assuaged with the company's Q3 2024 results. Market multiples for Novo Nordisk are also attractive ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

The site will manufacture various types of rare disease drugs, including those for the treatment ... said. Novo Nordisk, which has become Europe's most valuable listed company on the back of ...

However, shares of Novo Nordisk have fallen ... They see the entire MASH treatment market worth nearly $10 billion a year. Phase 3 trial results suggest that Novo could take a large part of ...

The site will manufacture various types of rare disease drugs, including those for the treatment ... said. Novo Nordisk, which has become Europe's most valuable listed company on the back of ...